Biocon Pharma Inc. secured FDA approval for its generic oral formulation of Dapagliflozin via ANDA211470, with the product slated for a market entry in April 2026. This regulatory milestone is expected to intensify competition within the diabetes treatment sector, positioning Biocon to challenge established players and potentially impact branded pricing dynamics in the U.S. market.